Imaging genomics attempts to integrate molecular characteristics of tumors, including gene expression data, with imaging features derived from MRI, CT, PET or other imaging modalities in order to acquire a panoramic and informative assessment of tumor status including surveillance of oncogenic pathways. Integration of these large datasets can extend the utility and impact of serial imaging to non-invasively follow tumor biology over the treatment course. In particular, improved clinical decision making based on more accurate predictive and prognostic markers is potentially achievable, as are methods to improve understanding of tumor biology and streamline the selection and validation of therapeutic targets. Quantitative imaging data acquisition in combination with stereospecific tumor biopsies should yield further refinements and improvements to this approach. The study group focuses on the application of imaging-genomics to high grade gliomas and in particular glioblastoma, attempting to identify further areas of exploration where understanding the relationship between imaging data and tumor molecular features has potential in achieving optimally personalized medicine.
- Explore the relationship between molecular markers of malignancy and qualitative and quantitative imaging features of brain tumors.
- Understand the potential and limitations of genomic-imaging correlates for assessing tumor biology in patients with glioblastoma.
- Leverage Imaging-Genomic correlates to improve clinical decision making at the individual patient level and to improve patient selection for multicenter drug trials.